GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Cyclically Adjusted Price-to-FCF

Blueprint Medicines (FRA:2L9) Cyclically Adjusted Price-to-FCF : (As of Jun. 18, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Blueprint Medicines's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Cyclically Adjusted Price-to-FCF Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Blueprint Medicines's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Blueprint Medicines's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Cyclically Adjusted Price-to-FCF falls into.



Blueprint Medicines Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Blueprint Medicines's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Blueprint Medicines's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.48/131.7762*131.7762
=-1.480

Current CPI (Mar. 2024) = 131.7762.

Blueprint Medicines Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.487 100.560 -0.638
201409 -0.519 100.428 -0.681
201412 -0.743 99.070 -0.988
201503 0.181 99.621 0.239
201506 -0.591 100.684 -0.774
201509 -0.441 100.392 -0.579
201512 -0.570 99.792 -0.753
201603 0.978 100.470 1.283
201606 -0.602 101.688 -0.780
201609 -0.626 101.861 -0.810
201612 -0.627 101.863 -0.811
201703 -0.881 102.862 -1.129
201706 -0.637 103.349 -0.812
201709 -0.665 104.136 -0.842
201712 -0.957 104.011 -1.212
201803 -1.037 105.290 -1.298
201806 -0.121 106.317 -0.150
201809 -1.125 106.507 -1.392
201812 -1.359 105.998 -1.690
201903 -1.645 107.251 -2.021
201906 -1.511 108.070 -1.842
201909 -1.446 108.329 -1.759
201912 -0.892 108.420 -1.084
202003 -1.905 108.902 -2.305
202006 -1.672 108.767 -2.026
202009 9.304 109.815 11.165
202012 -0.360 109.897 -0.432
202103 -1.823 111.754 -2.150
202106 -0.907 114.631 -1.043
202109 -1.400 115.734 -1.594
202112 -4.104 117.630 -4.598
202203 -2.050 121.301 -2.227
202206 -1.917 125.017 -2.021
202209 -2.258 125.227 -2.376
202212 -1.937 125.222 -2.038
202303 -1.950 127.348 -2.018
202306 -2.029 128.729 -2.077
202309 -1.710 129.860 -1.735
202312 -1.259 129.419 -1.282
202403 -1.480 131.776 -1.480

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (FRA:2L9) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Blueprint Medicines Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (FRA:2L9) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines